Stifel resumed coverage of Kymera Therapeutics (KYMR) with a Buy rating and $55 price target The company “sits squarely within the next wave of development” across the immunology and inflammation space by pushing forward a degrader platform, the analyst tells investors in a research note. The firm thinks Kymera’s lead program KT-621 has a shot at achieving efficacy in the range of Dupixent–a product profile that currently does not exist in atopic dermatitis, and could garner meaningful share in the “still nascent market with optionality beyond.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics presents preclinical data for KT-621
- Kymera Therapeutics price target lowered to $70 from $72 at UBS
- Kymera Therapeutics’ Innovative IRF5 Degrader KT-579 Fuels Buy Rating with Promising Growth in Immunology
- Kymera Therapeutics price target lowered to $38 from $41 at B. Riley
- Kymera Therapeutics: Innovative Approaches in Autoimmune Disease Treatment Drive Buy Rating